Clinuvel Pharmaceuticals Ltd (CLVLY.PK) Key Developments | Reuters.com
Edition:
United States

Clinuvel Pharmaceuticals Ltd (CLVLY.PK)

CLVLY.PK on OTC Markets Group

3.27USD
29 Jun 2016
Change (% chg)

$0.05 (+1.55%)
Prev Close
$3.22
Open
$3.25
Day's High
$3.27
Day's Low
$3.25
Volume
1,708
Avg. Vol
10,918
52-wk High
$3.76
52-wk Low
$1.79

Latest Key Developments (Source: Significant Developments)

Clinuvel Pharmaceuticals announces inclusion of its ADR program in NASDAQ's international designation
Wednesday, 1 Jun 2016 06:24pm EDT 

Clinuvel Pharmaceuticals Ltd : Announced the inclusion of its sponsored level 1 American depository receipt (adr) program in NASDAQ's international designation .  Full Article

European Commission approves Clinuvel Pharmaceuticals Ltd's SCENESSE drug
Monday, 22 Dec 2014 08:30pm EST 

Clinuvel Pharmaceuticals Ltd:Says that the European Commission has ratified the recommendation of the European Medicines Agency (EMA), granting marketing approval under exceptional circumstances to Clinuvel’s drug SCENESSE.  Full Article

Clinuvel Pharmaceuticals Ltd's SCENESSE attains European marketing authorisation
Sunday, 26 Oct 2014 07:06pm EDT 

Clinuvel Pharmaceuticals Ltd:Says that European Medicines Agency's (EMA's) committee for medicinal products for human use (CHMP) has voted in favour of marketing authorisation (MA) of Clinuvel's drug SCENESSE (afamelanotide 16mg) for adult patients with erythropoietic protoporphyria (EPP).EPP is debilitating, rare genetic disorder clinically regarded as extreme intolerance to light and UV (phototoxicity).  Full Article

Clinuvel Pharmaceuticals Ltd announces SCENESSE vitiligo study results
Thursday, 18 Sep 2014 10:00pm EDT 

Clinuvel Pharmaceuticals Ltd:Announced the results from its US Phase IIa study of SCENESSE (afamelanotide 16mg) in vitiligo (CUV102).Says all of whom were the treating physicians in CUV102, reported that the drug was well tolerated and the combination therapy “resulted in clinically apparent, statistically significant superior and faster repigmentation compared with NB–UV‐B monotherapy”.Says it was also reported that patients with darker skin types (Fitzpatrick types IV‐VI) responded faster to the combination therapy.  Full Article

Retrophin Inc proposes acquisition of Clinuvel Pharmaceuticals
Sunday, 27 Jul 2014 11:47pm EDT 

Retrophin Inc:Says that on July 17, 2014 it submitted a proposal to the Board of Directors of Clinuvel Pharmaceuticals Ltd to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for 0.175 Retrophin shares per Clinuvel share, or A$2.17 per share in cash.Says Retrophin currently owns approximately 4.88 pct. of Clinuvel shares.  Full Article

No consensus analysis data available.